RE:RE:RE:RE:RE:RE:RE:RE:RE:This is it...
jmm1228 wrote: It is my belief that the potential impact on pharma firms now involved in cancer therapy is one of factors in the FDA's thinking as Ruvidar/PDTworks its way through the approval process and that this possible concern is making for a more intense scrutiny of Theralase's breakthrough treatment.
The potential impact this treatment appears to be one that it could unseat nearly all of the currently approved and employed practices - it is likely to be very disruptive, if in fact the long term results establish the promise on a wider scope, the treatment will be a colossal game changer.
Medicine has seen such happenings in many forms for decades.
Therelase should be under harsher scrutiny because iof this and because of the nature of its neophyte construct in the pharma industry.
If so, no wonder it is taking so long.
All solely my opinion.
I agree, especially regarding the wider scope. What we have accomplished is truly mind bending in comparison to other options available but when you factor in the possibility of using this off label and treating people who haven't been defiled by months and months of other treatments or treating bladder cancer that isn't BCG unresponsive.
I feel if this gains traction the wider scope will be phenomenal